Browse Category

NYSE:PFE 6 December 2025 - 16 December 2025

For live price, interactive charts, financials and the latest market data, visit Google Finance.
Pfizer Shares Offer 6.4% Yield, Surpassing Wall Street Optimism After Results
Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Stock (PFE) Slides After 2026 Guidance: COVID Sales Drop, Patent Cliff and Analyst Forecasts in Focus

Pfizer Inc. shares fell sharply in U.S. trading on Tuesday, December 16, 2025, as investors weighed the drugmaker’s first look at full-year 2026 guidance, an updated 2025 revenue outlook, and fresh commentary on cost savings and capital allocation. By late morning ET, Pfizer stock was trading around $25, down roughly 5% on the day after swinging between the mid-$26s and just under $25.
16 December 2025
····
Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next

Pfizer Stock (PFE) News and Forecast for Dec. 14, 2025: Dividend, Obesity Deal, Oncology Catalysts, and What Analysts Expect Next

Pfizer Inc. is ending the week in a familiar spot—trading in the mid‑$20s—while investors weigh a high dividend payout against a fast-moving set of catalysts: new oncology data from the Seagen portfolio, a fresh attempt at an oral obesity drug, ongoing cost-cutting, and a looming shift in the U.S. COVID vaccine policy backdrop. Reuters+3StockAnalysis+3Reuters+3
14 December 2025
··
Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Healthcare & Pharma Giants US Stocks: Week Ahead Outlook After Eli Lilly’s Retatrutide, CVS Guidance, Pfizer’s Obesity Deal, and J&J’s Talc Verdict (Updated Dec. 14, 2025)

Wall Street heads into the week of Dec. 15, 2025 with U.S. healthcare and pharma mega-caps back in the spotlight—pulled by three powerful forces that all intensified in the last seven days: the obesity-drug arms race, Washington’s policy crosscurrents around insurance subsidies and PBM transparency, and a faster-moving FDA that is simultaneously accelerating reviews and reopening safety scrutiny in sensitive pediatric categories. Reuters+3Reuters+3Reuters+3
14 December 2025
······
Pfizer Stock (PFE) Outlook: GLP‑1 Weight‑Loss Deal, Tukysa Trial Win, Dividend Declared — and the Big Catalyst Next Week (Updated Dec. 12, 2025)

Pfizer Stock (PFE) Outlook: GLP‑1 Weight‑Loss Deal, Tukysa Trial Win, Dividend Declared — and the Big Catalyst Next Week (Updated Dec. 12, 2025)

Pfizer heads into the final full trading week before the holidays with a familiar mix of catalysts: pipeline updates that support its post‑COVID growth narrative, dealmaking in the red‑hot obesity space, and renewed regulatory headlines around COVID‑19 vaccines. Add in a freshly declared quarterly dividend and an upcoming 2026 guidance call, and Pfizer stock is setting up for another headline-driven stretch.
13 December 2025
···
Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer (PFE) Stock After Hours on Dec. 12, 2025: Dividend Update, FDA Vaccine Warning Headlines, and What to Watch Before the Next Market Open

Pfizer Inc. ended the Friday, December 12, 2025 session slightly higher—and moved only modestly in after-hours trading—after a busy day of headline-driven catalysts. Investors weighed a newly declared $0.43 quarterly dividend, fresh FDA-related reporting tied to COVID-19 vaccine labeling, and late-stage oncology data involving Pfizer’s breast-cancer drug Tukysa. Reuters+3StockAnalysis+3Pfizer+3
13 December 2025
··
Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer (PFE) Stock After Hours on December 9, 2025: Obesity Pill Deal, RSV Questions, and What to Watch Before the Opening Bell

Pfizer Inc. finished a volatile Tuesday session on December 9, 2025 under pressure, then stabilized in after-hours trading as investors digested a big new obesity-drug licensing deal and fresh headlines around RSV therapies. With the next U.S. market session opening on December 10, 2025, traders in Pfizer stock are lining up the key catalysts that could drive PFE’s next move.
10 December 2025
····
Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer Inc. is back in focus on December 8, 2025, as investors digest fresh clinical data in hemophilia, big strategic bets in obesity drugs, and an aggressive, AI‑driven cost‑cutting program – all while the stock continues to trade at a high dividend yield and a discount to many Big Pharma peers.
8 December 2025
···
1 … 6 7 8 9 10 … 12
Follow on Google News
Add as preferred source Open in Google News
AI PORTFOLIO

Top Stock Picks

Today’s highest-ranked model selections.

#1 STRONG BUY

AerCap

NYSE: AER 95 / 100
#2 BUY

Constellation Energy

NASDAQ: CEG 94 / 100
#3 BUY ON PULLBACK

Cheniere Energy

NYSE: LNG 92 / 100
#4 BUY

Walt Disney

NYSE: DIS 90 / 100
#5 ACCUMULATE

AIG

NYSE: AIG 88 / 100
View full portfolio
Editorial model selection. Not personalised advice.